ES8403722A1 - Procedimiento para inactivar el virus de la hepatitis b. - Google Patents

Procedimiento para inactivar el virus de la hepatitis b.

Info

Publication number
ES8403722A1
ES8403722A1 ES521431A ES521431A ES8403722A1 ES 8403722 A1 ES8403722 A1 ES 8403722A1 ES 521431 A ES521431 A ES 521431A ES 521431 A ES521431 A ES 521431A ES 8403722 A1 ES8403722 A1 ES 8403722A1
Authority
ES
Spain
Prior art keywords
plasma
factor viii
sterilized
derivatives
process therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES521431A
Other languages
English (en)
Other versions
ES521431A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23450479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8403722(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Publication of ES8403722A1 publication Critical patent/ES8403722A1/es
Publication of ES521431A0 publication Critical patent/ES521431A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Lubricants (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

PROCEDIMIENTO PARA INACTIVAR EL VIRUS DE LA HEPATITIS B EN EL PLASMA O UN CONCENTRADO DE PLASMA SANGUINEO.CONSISTE EN TRATAR EL PLASMA O CONCENTRADO DE PLASMA CON UN AGENTE INACTIVANTE VIRAL TAL COMO UN ETER O UNA MEZCLA DE UN ETER CON, AL MENOS, UN DETERGENTE NO IONICO Y/O UN ALCOHOL, DURANTE 1 MINUTO COMO MINIMO, A UNA TEMPERATURA COMPRENDIDA ENTRE C5JC Y 50JC. LOS AGENTES VIRALES DEBEN ESTAR EN UNA PROPORCION ENTRE EL 0,1 Y 50 SOBRE EL PESO DEL PLASMA.TIENE APLICACIONES PARA LA PREPARACION DE PLASMA EMPLEADO PARA VACUNAS VIRICAS CONTRA HBV.
ES521431A 1982-04-14 1983-04-13 Procedimiento para inactivar el virus de la hepatitis b. Granted ES521431A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/368,250 US4481189A (en) 1982-04-14 1982-04-14 Process for preparing sterilized plasma and plasma derivatives

Publications (2)

Publication Number Publication Date
ES8403722A1 true ES8403722A1 (es) 1984-04-01
ES521431A0 ES521431A0 (es) 1984-04-01

Family

ID=23450479

Family Applications (1)

Application Number Title Priority Date Filing Date
ES521431A Granted ES521431A0 (es) 1982-04-14 1983-04-13 Procedimiento para inactivar el virus de la hepatitis b.

Country Status (13)

Country Link
US (1) US4481189A (es)
EP (1) EP0099445B2 (es)
JP (1) JPH0660105B2 (es)
AT (1) ATE58835T1 (es)
AU (1) AU561900B2 (es)
CA (1) CA1207229A (es)
DE (1) DE3382042D1 (es)
DK (1) DK164537C (es)
ES (1) ES521431A0 (es)
FI (1) FI80211C (es)
NO (1) NO163514C (es)
NZ (1) NZ203878A (es)
ZA (1) ZA832239B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581231A (en) * 1982-06-10 1986-04-08 The United States Of America As Represented By The Secretary Of Health And Human Services Inactivation of viruses containing essential lipids
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
CA1254839A (en) * 1984-08-14 1989-05-30 Mark W. Torrianni Retarded mineralization of implantable tissue by surface active betaines
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
US4613501A (en) * 1984-12-21 1986-09-23 New York Blood Center, Inc. Inactivation of viruses in labile blood derivatives
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4971760A (en) * 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
US5211912A (en) * 1986-08-01 1993-05-18 University Of Southern California Method for disinfecting red blood cells, blood products, and corneas
US5185371A (en) * 1986-03-10 1993-02-09 University Of Southern California Method for disinfecting red blood cells
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
AT390374B (de) * 1986-03-18 1990-04-25 Schwab & Co Gmbh Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen
US4789545A (en) * 1986-03-31 1988-12-06 New York Blood Center, Inc. Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US4944920A (en) * 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
AU6942387A (en) * 1986-08-01 1988-03-24 Rubinstein, A.I. A method to treat blood
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US4869826A (en) * 1987-09-01 1989-09-26 Process Biotechnology, Inc. Cellular adsorbents for removal of viral contaminants from blood and complex protein solutions
DE3733181C1 (de) * 1987-10-01 1989-01-19 Biotest Pharma Gmbh Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
DE3805459A1 (de) * 1988-02-22 1989-08-31 Biotest Pharma Gmbh Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
DE3826792C1 (es) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4125625C2 (de) * 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
EP0707633A4 (en) * 1993-06-23 1996-08-14 New York Blood Center Inc SYSTEM FOR VIRAL INACTIVATION OF BLOOD
DE69433759T2 (de) 1993-07-30 2005-03-31 Aruba International Pty. Ltd., Rocklea Plasmadelipidationssystem
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
FR2716111B1 (fr) * 1994-02-11 1996-11-08 Cogia Procédé de préparation d'une composition cosmétique ou alimentaire apte à être conservée, dispositif et composition de longue conservation.
US5486293A (en) * 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
EP0771324B2 (fr) † 1994-07-14 2011-02-09 CAF-DCF Département Central de Fractionnement de la Croix Rouge S.C.R.L. Concentre de fibrinogene issu de plasma sanguin, procede et installation pour sa preparation
AUPN030794A0 (en) 1994-12-22 1995-01-27 Aruba International Pty Ltd Discontinuous plasma or serum delipidation
FI952196A0 (fi) * 1995-05-08 1995-05-08 Suomen Punainen Risti Veripalv Framstaellning av immunoglobulin
AU5929896A (en) * 1995-05-26 1996-12-11 Sadeque S. Naficy Apparatuses and methods for treatment of blood
DE19528221C2 (de) * 1995-08-01 1998-10-22 Blutspendedienst Der Drk Lande Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
DK2130554T3 (da) 1999-02-22 2012-12-03 Univ Connecticut Albuminfrie faktor VIII-præparater
US6436344B1 (en) 1999-11-02 2002-08-20 American National Red Cross Method of inactivating pathogens
CA2394797A1 (en) * 1999-12-20 2001-06-28 Tsuyoshi Takahashi Process for producing virus-free plasma protein composition by porous membrane treatment, virus-free plasma protein composition and method of removing viruses
DE60039786D1 (de) * 1999-12-22 2008-09-18 Univ Pennsylvania Kosmid-dns-konstrukte und verfahren für deren herstellung und verwendung
AUPQ486699A0 (en) * 1999-12-23 2000-02-03 Aruba International Pty Ltd A method of treating infectious diseases
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
WO2003000372A2 (en) 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
AU2004216476B2 (en) * 2003-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Method for the validatable inactivation of pathogens in a biological fluid by irradiation
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
PT1641421T (pt) 2003-07-03 2019-03-27 Hdl Therapeutics Inc Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7993580B2 (en) * 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
EP1685852A1 (en) * 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids
RU2468032C2 (ru) * 2006-06-26 2012-11-27 Омрикс Биофармасьютикалс Инк. Способ очистки раствора тромбина от инфекционных частиц
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
CN101977635A (zh) * 2008-03-28 2011-02-16 医疗器械研究基金会 通过溶剂/去污剂处理对生物流体进行病毒灭活的方法
AU2009313325B2 (en) 2008-11-07 2014-05-01 Takeda Pharmaceutical Company Limited Factor VIII formulations
EP2399613A1 (en) 2010-06-22 2011-12-28 Research Foundation For Medical Devices Fractionation of plasma using caprylic acid
CN106138851A (zh) * 2016-09-08 2016-11-23 四川聚豪生物科技有限公司 一种可有效治疗乙肝的汤剂药物及其制备方法
US11027052B2 (en) 2017-11-22 2021-06-08 HDL Therapuetics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
EP3731814A4 (en) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. PROCESSES FOR THE STORAGE AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEINS EXTRACTED FROM HUMAN PLASMA
CA3121200A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
US11529587B2 (en) 2019-05-03 2022-12-20 Cellphire, Inc. Materials and methods for producing blood products
WO2021046409A1 (en) * 2019-09-05 2021-03-11 Cellphire, Inc. Materials and methods for blood plasma preparations
CA3170201A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
GB1507215A (en) * 1975-08-19 1978-04-12 Green Cross Corp Processes for producing immunoregulatory preparations
US4057628A (en) * 1976-04-19 1977-11-08 William L. Wilson Removal of hepatitis associated antigen from plasma
US4222934A (en) * 1979-04-12 1980-09-16 American National Red Cross Preparation of albumin using ethanol
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
DE3033932C2 (de) 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process

Also Published As

Publication number Publication date
FI80211C (fi) 1990-05-10
ATE58835T1 (de) 1990-12-15
NO163514C (no) 1990-06-13
EP0099445B2 (en) 1998-07-08
JPS58222023A (ja) 1983-12-23
CA1207229A (en) 1986-07-08
DK162983D0 (da) 1983-04-13
FI831146L (fi) 1983-10-15
DK164537C (da) 1992-11-30
JPH0660105B2 (ja) 1994-08-10
EP0099445B1 (en) 1990-12-05
DK162983A (da) 1983-10-15
NO831304L (no) 1983-10-17
NZ203878A (en) 1986-02-21
FI831146A0 (fi) 1983-04-05
AU561900B2 (en) 1987-05-21
AU1346283A (en) 1983-10-20
US4481189A (en) 1984-11-06
ES521431A0 (es) 1984-04-01
EP0099445A3 (en) 1985-01-16
FI80211B (fi) 1990-01-31
DK164537B (da) 1992-07-13
EP0099445A2 (en) 1984-02-01
NO163514B (no) 1990-03-05
DE3382042D1 (de) 1991-01-17
ZA832239B (en) 1984-11-28

Similar Documents

Publication Publication Date Title
EP0099445A3 (en) Sterilized plasma and plasma derivatives and process therefor
US4613501A (en) Inactivation of viruses in labile blood derivatives
DE3483499D1 (de) Nichtdenaturierte virusfreie biologisch aktive proteinderivate.
ES8705764A1 (es) Procedimiento fotodinamico de inactivacion de virus
EP0519901A3 (en) Virus-inactivated blood product
EP1852121A3 (en) Lipid analogs for treating viral infections
ES8503721A1 (es) "un metodo de inactivar un virus lipidico"
ES8608577A1 (es) Un metodo para inactivar virus que contienen lipidos esen- ciales en un vehiculo proteinico seco
DE68923169D1 (de) Verwendung von fluor enthaltenden Pyridoncarbonsäure-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von HIV infektionen.
YU18900A (sh) Postupak za čišćenje hirurških instrumenata
ES8802579A1 (es) Procedimiento de obtencion de un aditivo concentrado para el ciclo de aclarado de lavavajillas
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
EP0281978A3 (en) Inactivation of human immunodeficiency virus (hiv) in proteinic solutions by means of phenol
NZ516372A (en) Method for stabilising proteins in complex mixtures during their storage in aqueous solvents
JPS5545618A (en) Thermal treatment of fraction containing glycoprotein which accelerates differentiation and proliferation of human granulocyte
ES8506449A1 (es) Procedimiento para la obtencion de preparados a partir de plasma humano
JPS6419023A (en) Heat treatment of fibrinogen and fibrinogen preparation
Lane et al. THE NEW YORK BLOOD CENTER

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20021115